Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1992-02-27
1994-08-09
Hill, Jr., Robert J.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, 4241831, 4241441, 514 2, 514 8, A61K 3702, A61K 3764, A61K 39395
Patent
active
053364899
ABSTRACT:
A method of lysing unwanted, non-malignant cells in a mammal, the cells having on their surfaces a receptor for a growth factor, and the method including administering to the mammal a cell-lysing amount of a substance characterized in that it has specific affinity for the receptor of the growth factor and has the ability to effect the lysis of the cells.
REFERENCES:
patent: 4388309 (1983-06-01), Fabricius
patent: 4440747 (1984-04-01), Neville
patent: 4675382 (1987-06-01), Murphy
Lorberboum-Galski, H., et al. (1989) Proc. Natl. Acad. Sci. USA 86:1008-1012.
Knox, R., "Researchers find new way to stop organ rejection"; Boston Globe, May 5, 1985, p. 20.
Kelley, V. E., et al. (1988) J. Immunol. 140: 59-61.
Takahashi et al. (1983) The Lancet pp. 1155-1158.
Williams et al. (1984) J. Immunol. 132 (5), 2330.
Kirkman et al. (1983) Transplantation 36 (6), 620.
Zubler et al. (1984) J. Exper. Med. 160 (4), 1170.
Leonard et al. (1982) Nature 300, 267.
FitzGerald et al. (1984) J. Clin. Invest. 74, 966.
Depper et al. (1983) J. Immunol. 131 (2), 690.
Cotner et al. (1983) Journal of Experimental Medicine 157 461-472.
Fitzgerald David L.
Hill Jr. Robert J.
The Beth Israel Hospital Association
LandOfFree
Treatment of allograft rejection with IL-2 receptor-specific cyt does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of allograft rejection with IL-2 receptor-specific cyt, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of allograft rejection with IL-2 receptor-specific cyt will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-214828